Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Staying on obesity treatment pays off long-term. A large Cleveland Clinic study found that adults on semaglutide or tirzepatide who kept up some form of obesity therapy — whether switching drugs or having bariatric surgery — maintained meaningful weight loss at 2 years. Those who quit treatment altogether lost just 3.9% of body weight, compared to up to 26.6% for surgery patients.
Sticking with obesity treatment matters more than which drug you're on. A new real-world study from Cleveland Clinic, presented at ObesityWeek 2026, found that adults using semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) who continued any form of obesity therapy maintained meaningful weight loss at 2 years — while those who stopped treatment saw results nearly disappear.
The analysis tracked over 20,000 adults across five treatment strategies. Bariatric surgery delivered the biggest results, but even switching between GLP-1 medications outperformed staying on the same drug — particularly for those who moved from semaglutide to tirzepatide.
By the Numbers:
Why it matters: With GLP-1 drug shortages, cost barriers, and side effects prompting many patients to stop or switch medications, this study gives clinicians real-world data to guide those conversations — and a strong case for keeping patients engaged in obesity care rather than stopping altogether.